Incidence of tuberculosis in Korean patients with Rheumatoid Arthritis (RA): Effects of RA itself and of tumor necrosis factor blockers

Journal of Rheumatology

Volumn 34, Issue 4, 2007, Pages 706-711

  Seong, Sang Seokg ^a,b   Choi, Chan Bum ^a,b   Woo, Jin Hyun ^a,b   Kang, Woo Bae ^a,b   Joung, Chung Li ^b   Uhm, Wan Sik ^a,b   Kim, Tae Hwan ^a,b   Jun, Jae Bum ^a,b   Yoo, Dae Hyun ^a,b   Lee, Jong Tae ^c   Bae, Sang Cheol ^a,b,d  

^a Hanyang University   (South Korea)

^b Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^c Konyang University   (South Korea)

^d Hanyang University Medical Center   (South Korea)

Author keywords

Etanercept; Infliximab; Rheumatoid arthritis; Tuberculosis

Indexed keywords

BUCILLAMINE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFECTION RISK; KOREA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; TUBERCULOSIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; COHORT STUDIES; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; KOREA; MALE; MIDDLE AGED; ODDS RATIO; RECEPTORS, TUMOR NECROSIS FACTOR; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247332718     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86.
2. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
3. Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000;27:841-50.
4. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
5. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
6. Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 2004;16:393-8.
7. Fenhalls G, Wong A, Bezuidenhout J, van Helden P, Bardin P, Lukey PT. In situ production of gamma interferon, interleukin-4, and tumor necrosis factor alpha mRNA in human lung tuberculous granulomas. Infect Immun 2000;68:2827-36.
8. Kaplan G, Freedman VH. The role of cytokines in the immune response to tuberculosis. Res Immunol 1996;147:565-72.
9. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-92.
10. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
11. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
12. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004;39:295-9.
13. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9.
14. Rajagopalan S. Tuberculosis and aging: a global health problem. Clin Infect Dis 2001;33:1034-9.
15. Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293:2756-61.
16. Korean National Tuberculosis Association [monograph on the Internet, accessed Jan 3 2007]. Available from: http://www.knta.or.kr/korea/study/study05. asp
17. WHO. Global tuberculosis control. Surveillance, planning, financing. [Monograph on the Internet, accessed Jan 3, 2007]. Available from: http://www.who.int/tb/publications/global_report/en/.
18. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
19. Centers for Disease and Prevention (CDC). Trends in tuberculosis- United States, 2005. MMWR Morb Mortal Wkly Rep 2006;55:305-8.
20. Bouza E, Moya JG, Munoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 2001;15:335-61.
21. Rovensky J, Kovalancik M, Kristufek P, et al. Contribution to the problem of occurrence of tuberculosis in patients with systemic lupus erythematosus. Z Rheumatol 1996;55:180-7.
22. Carmona L, Hernandez-Garcia C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436-9.
23. Yun JE, Lee SW, Kim TH, et al. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol 2002;20:127-32.
24. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
25. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.
26. Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha, California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004;53:683-6.
27. Baldin B, Dozol A, Spreux A, Chichmanian RM. Tuberculosis and infliximab treatment. National surveillance from January 1, 2000, through June 30, 2003 [French]. Presse Med 2005;34:353-7.
28. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
29. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85.
30. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26.
31. Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003;168:1153-6.
32. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55.
33. Paimela L, Johansson-Stephansson EA, Koskimies S, Leirisalo-Repo M. Depressed cutaneous cell-mediated immunity in early rheumatoid arthritis. Clin Exp Rheumatol 1990;8:433-7.
34. Pai M, Gokhale K, Joshi R, Dogra S, et al. Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing. JAMA 2005;293:2746-55.
35. Pai M, Riley LW, Colford JM, Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4:761-76.